These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 29127678)

  • 1. Allogeneic/Matched Related Transplantation for β-Thalassemia and Sickle Cell Anemia.
    Bernaudin F; Pondarré C; Galambrun C; Thuret I
    Adv Exp Med Biol; 2017; 1013():89-122. PubMed ID: 29127678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience.
    Zaidman I; Rowe JM; Khalil A; Ben-Arush M; Elhasid R
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1043-1048. PubMed ID: 27016193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
    Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
    JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infectious complications following allogeneic stem cell transplantation by using anti-thymocyte globulin-based myeloablative conditioning regimens in children with hemoglobinopathies.
    Goussetis E; Efstathiou E; Paisiou A; Avgerinou G; Zisaki K; Giamouris VJ; Peristeri I; Kitra V; Vessalas G; Gamaletsou MN; Sipsas NV; Graphakos S
    Transpl Infect Dis; 2015 Apr; 17(2):201-7. PubMed ID: 25645592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin.
    Soni S; Gross TG; Rangarajan H; Baker KS; Sturm M; Rhodes M
    Pediatr Blood Cancer; 2014 Sep; 61(9):1685-9. PubMed ID: 24740582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells.
    Kharbanda S; Smith AR; Hutchinson SK; McKenna DH; Ball JB; Lamb LS; Agarwal R; Weinberg KI; Wagner JE
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):581-6. PubMed ID: 24370862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Results of hematopoietic stem cell transplantation in hemoglobinopathies: thalassemia major and sickle cell disease].
    Hladun R; Elorza I; Olivé T; Dapena JL; Llort A; Sánchez de Toledo J; Díaz de Heredia C
    An Pediatr (Barc); 2013 Aug; 79(2):75-82. PubMed ID: 23402775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic Stem Cell Transplantation in Patients with Hemoglobinopathies.
    Yesilipek MA
    Hemoglobin; 2020 Nov; 44(6):377-384. PubMed ID: 33050763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic cellular gene therapy for hemoglobinopathies.
    Gaziev J; Lucarelli G
    Hematol Oncol Clin North Am; 2010 Dec; 24(6):1145-63. PubMed ID: 21075285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France.
    Bernaudin F; Dalle JH; Bories D; de Latour RP; Robin M; Bertrand Y; Pondarre C; Vannier JP; Neven B; Kuentz M; Maury S; Lutz P; Paillard C; Yakouben K; Thuret I; Galambrun C; Dhedin N; Jubert C; Rohrlich P; Bay JO; Suarez F; Raus N; Vernant JP; Gluckman E; Poirot C; Socié G;
    Haematologica; 2020 Jan; 105(1):91-101. PubMed ID: 31097628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Goal-Oriented Monitoring of Cyclosporine Is Effective for Graft-versus-Host Disease Prevention after Hematopoietic Stem Cell Transplantation in Sickle Cell Disease and Thalassemia Major.
    Gauthier A; Bleyzac N; Garnier N; Kebaili K; Joly P; Goutagny MP; Mollet I; Goutelle S; Renard C; Bertrand Y
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2285-2291. PubMed ID: 32007639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-matched sibling stem cell transplantation in children with β-thalassemia with anti-thymocyte globulin as part of the preparative regimen: the Greek experience.
    Goussetis E; Peristeri I; Kitra V; Vessalas G; Paisiou A; Theodosaki M; Petrakou E; Dimopoulou MN; Graphakos S
    Bone Marrow Transplant; 2012 Aug; 47(8):1061-6. PubMed ID: 22080966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease.
    Wiebking V; Hütker S; Schmid I; Immler S; Feuchtinger T; Albert MH
    Ann Hematol; 2017 Aug; 96(8):1373-1377. PubMed ID: 28573314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin.
    Horan JT; Liesveld JL; Fenton P; Blumberg N; Walters MC
    Bone Marrow Transplant; 2005 Jan; 35(2):171-7. PubMed ID: 15531901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in allogeneic stem cell transplantation for hemoglobinopathies.
    Al Jefri AH
    Hemoglobin; 2011; 35(5-6):469-75. PubMed ID: 21967642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia.
    Lucarelli G; Isgrò A; Sodani P; Gaziev J
    Cold Spring Harb Perspect Med; 2012 May; 2(5):a011825. PubMed ID: 22553502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transplantation for thalassemia major: alternative donors.
    Locatelli F; Merli P; Strocchio L
    Curr Opin Hematol; 2016 Nov; 23(6):515-523. PubMed ID: 27537474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation.
    Shenoy S; Angelucci E; Arnold SD; Baker KS; Bhatia M; Bresters D; Dietz AC; De La Fuente J; Duncan C; Gaziev J; King AA; Pulsipher MA; Smith AR; Walters MC
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):552-561. PubMed ID: 28065838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Saudi experience in fludarabine-based conditioning regimens in patients with Fanconi anemia undergoing stem cell transplantation: excellent outcome in recipients of matched related stem cells but not in recipients of unrelated cord blood stem cells.
    Ayas M; Al-Seraihi A; El-Solh H; Al-Ahmari A; Khairy A; Aldali A; Markiz S; Siddiqui K; Al-Jefri A
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):627-32. PubMed ID: 21871862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
    Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Kim CK; Lee KT; Won JH; Hong DS
    Korean J Intern Med; 2016 Jul; 31(4):750-61. PubMed ID: 27017944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.